# Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

> **NCT02260661** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 20 (actual)

## Conditions studied

- Advanced Solid Malignancies
- Breast Cancer - ER+, HER2 -
- Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation

## Interventions

- **DRUG:** AZD8835
- **DRUG:** AZD8835
- **DRUG:** AZD8835 in combination with fulvestrant
- **DRUG:** AZD8835 in combination with fulvestrant

## Key facts

- **NCT ID:** NCT02260661
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02260661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02260661, "Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02260661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*